Clinical summary
Summary
This is a non-randomised trial with one experimental arm, designed to assess the safety of chemo-radiotherapy-immunotherapy combination in patients with operable oesophageal and gastroeosophageal junction cancer. All participants will receive 5 weeks of weekly carboplatin-paclitaxel-radiotherapy. Avelumab will be given as intravenous infusion at the dose of 10mg/kg over 60 minutes in 250ml sodium chloride 0.9% every 2 weeks concurrently with chemoradiotherapy. A further two doses of 2 weekly avelumab will then be given alone.Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Merck
Scientific Title
Neoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary Efficacy